We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+13.8%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$14.5B
AUM Growth
+$1.96B
Cap. Flow
+$582M
Cap. Flow %
4.02%
Top 10 Hldgs %
31.8%
Holding
146
New
31
Increased
52
Reduced
23
Closed
24

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$319M
2
IMMU
Immunomedics Inc
IMMU
+$296M
3
GOOG icon
Alphabet (Google) Class C
GOOG
+$216M
4
NYT icon
New York Times
NYT
+$130M
5
HLT icon
Hilton Worldwide
HLT
+$129M

Top Sells

Rank Stock Value
1
PPLI
People Inc
PPLI
+$456M
2
WUBA
58.com Inc
WUBA
+$268M
3
CRM icon
Salesforce
CRM
+$181M
4
QGEN icon
Qiagen
QGEN
+$123M
5
CZR
Caesars Entertainment Corporation
CZR
+$97.2M

Sector Composition

Rank Sector Weight
1 Healthcare 40.81%
2 Communication Services 17.58%
3 Technology 8.21%
4 Financials 7.39%
5 Industrials 5.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KSU
51
DELISTED
Kansas City Southern
KSU
$71.2M 0.49%
+394,000
New +$68.2M
BRMK
52
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
$70.7M 0.49%
7,170,213
– –
APLS
53
DELISTED
Apellis Pharmaceuticals
APLS
$68.6M 0.47%
2,275,000
+25,000
+1% +$747K
PCG icon
54
PG&E
PCG
$38.5B
$68.5M 0.47%
+7,292,042
New +$67.6M
GBIO
55
DELISTED
Generation Bio
GBIO
$65.5M 0.45%
212,063
+181
+0.1% +$43.3K
SAGE
56
DELISTED
Sage Therapeutics
SAGE
$64.2M 0.44%
1,050,000
+200,000
+24% +$10.1M
EFX icon
57
Equifax
EFX
$21.4B
$62.2M 0.43%
396,484
+141,140
+55% +$23.1M
GRFS
58
Grifois
GRFS
$5.4B
$54.3M 0.38%
3,128,750
+15,528
+0.5% +$274K
KRTX
59
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$54.1M 0.37%
700,000
+125,000
+22% +$10.7M
PTGX icon
60
Protagonist Therapeutics
PTGX
$9.44B
$53.8M 0.37%
2,750,000
+250,000
+10% +$4.69M
ARNA
61
DELISTED
Arena Pharmaceuticals Inc
ARNA
$47.1M 0.33%
629,886
-270,114
-30% -$18M
CYTK icon
62
Cytokinetics
CYTK
$10.4B
$46.5M 0.32%
2,150,000
+650,000
+43% +$15.2M
AMRS
63
DELISTED
Amyris Inc.
AMRS
$40.9M 0.28%
14,000,000
+6,990,473
+100% +$25.6M
ANNX icon
64
Annexon
ANNX
$886M
$40.4M 0.28%
+1,657,261
New +$38.9M
ZGNX
65
DELISTED
Zogenix, Inc.
ZGNX
$40.3M 0.28%
2,250,000
+250,000
+13% +$6.13M
PACB icon
66
Pacific Biosciences
PACB
$370M
$40.1M 0.28%
4,063,770
+1,063,770
+35% +$6.12M
ZYME icon
67
Zymeworks
ZYME
$1.67B
$39.7M 0.27%
852,200
+302,200
+55% +$10.4M
AGIO icon
68
Agios Pharmaceuticals
AGIO
$1.93B
$37.9M 0.26%
1,083,429
-166,571
-13% -$7.3M
LNTH icon
69
Lantheus
LNTH
$6.59B
$33.6M 0.23%
2,650,000
+15,001
+0.6% +$206K
GBT
70
DELISTED
Global Blood Therapeutics, Inc.
GBT
$33.1M 0.23%
+600,000
New +$38.1M
ZNTL icon
71
Zentalis Pharmaceuticals
ZNTL
$302M
$32.4M 0.22%
991,174
– –
TVRD
72
Tvardi Therapeutics
TVRD
$23.4M
$28.6M 0.2%
62,500
-1,389
-2% -$807K
NVTA
73
DELISTED
Invitae Corporation
NVTA
$25.7M 0.18%
593,472
-63,056
-10% -$2.15M
RDUS
74
DELISTED
Radius Health, Inc.
RDUS
$23.9M 0.17%
2,107,400
+7,400
+0.4% +$91.5K
BRMK
75
CALL
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
$23.6M 0.16%
2,391,536
– –
1 2
3
4 5

Similar funds

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farallon Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Farallon Capital Management held 146 positions worth $14.5B, up 16% from $12.5B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Farallon Capital Management deployed $582M of net new capital in Q3 2020, opening 31 new positions and adding to 52 existing holdings. Its largest new stake was Boston Scientific: 8,275,919 shares worth $316M.

By sector, the portfolio is most concentrated in Healthcare at 41% of assets, down from 43% a quarter earlier, followed by Communication Services and Technology.

On the sell side, the largest reduction was Salesforce, an estimated $181M trimmed.

  • Farallon Capital Management's largest Q3 2020 buy was Boston Scientific: 8,275,919 shares worth $316M.
  • Farallon Capital Management added most to Alphabet (Google) Class C in Q3 2020, an estimated $216M increase.
  • Farallon Capital Management's biggest Q3 2020 reduction was Salesforce, cutting an estimated $181M.
  • Farallon Capital Management fully exited People Inc in Q3 2020, selling an estimated $456M.
  • Farallon Capital Management's ten largest holdings make up 32% of its $14.5B portfolio in Q3 2020.
  • Farallon Capital Management opened 31 new positions and closed 24 in Q3 2020.
  • Farallon Capital Management's portfolio value rose 16% quarter-over-quarter to $14.5B.

Based on Farallon Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.